Andres McAllister

Andres McAllister

Chief Tech/Sci/R&D Officer at BIOINVENT INTERNATIONAL AB

Net worth: 4 784 $ as of 2024-03-30

68 year
Health Technology
Consumer Services
Miscellaneous

Profile

Andres McAllister is currently the Chief Medical Officer at BioInvent International AB since 2017.
Prior to this, he worked as the Chief Scientific Officer at Debiopharm International SA from 2004 to 2015.
He also held positions as Director-Research & Development at Immune Design Corp., Non-Executive Director at Immunexpress Pty Ltd., and Principal at Institut Pasteur, The University of California, San Francisco, and Centre d'Immunologie Pierre Fabre.
Dr. McAllister holds a doctorate degree from Université Paris 1 Panthéon-Sorbonne and Universidad del Rosario.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
2022-12-30 3,009 ( 0.00% ) 4 784 $ 2024-03-30

Andres McAllister active positions

CompaniesPositionStart
BIOINVENT INTERNATIONAL AB Chief Tech/Sci/R&D Officer 2016-12-31
All active positions of Andres McAllister

Former positions of Andres McAllister

CompaniesPositionEnd
Chief Tech/Sci/R&D Officer 2015-08-31
Director/Board Member -
Centre d'Immunologie Pierre Fabre Corporate Officer/Principal -
Corporate Officer/Principal -
The University of California, San Francisco Corporate Officer/Principal -
See the detail of Andres McAllister's experience

Training of Andres McAllister

Université Paris 1 Panthéon-Sorbonne Doctorate Degree
Universidad del Rosario Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Andres McAllister's experience

Connections

36

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies1
BIOINVENT INTERNATIONAL AB

Health Technology

Private companies5

Miscellaneous

Health Technology

Health Technology

Health Technology

Centre d'Immunologie Pierre Fabre

See company connections
  1. Stock Market
  2. Insiders
  3. Andres McAllister